Dionysios Tsambaos, Elisabeth Chroni, Antonis S. Manolis, Alexandra Monastirli, Efi Pasmatzi, Theophilos Sakkis, Periklis Davlouros, Dimitrios Goumenos, Aggeliki Katrivanou, Sophia Georgiou
DOI: 10.1080/00015550410030682

Wepresent here the course of clinical response of a 53-year-oldhaemodialysed Fabry patient who received recombinant human α-galactosidase A at a dose of 1 mg/kg every other week over a period of 1 year. The therapy was well tolerated by the patient, who revealedan impressive favourable cutaneous, gastrointestinal, neurological andpsychiatric response and a dramatic improvement in his quality of life,but no improvement in cardiac and renal function.